ArticleMedicine2026
Prognostic determinants and survival outcomes in epithelioid sarcoma: A contemporary population-based analysis of 1123 patients.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: Primary epithelioid sarcoma of orbit: first case in Asia and literature review.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelioid sarcoma represents a rare and aggressive soft tissue malignancy characterized by SMARCB1/INI1 inactivation and propensity for local recurrence and distant metastasis. Comprehensive population-based analyses of prognostic determinants remain limited. We evaluated survival outcomes and identified independent prognostic factors using the Surveillance, Epidemiology, and End Results (SEER) database. We retrospectively analyzed 1123 patients diagnosed with epithelioid sarcoma between 2001 and 2022 from the SEER 17 registries database. Cox proportional hazards regression models were employed to identify prognostic factors for cancer-specific survival. Kaplan-Meier analysis with log-rank testing was performed for survival comparisons. The cohort comprised 634 males (56.5%) and 489 females (43.5%) with a mean age of 47.1 ± 21.3 years. Stage distribution revealed localized disease in 45.3%, regional involvement in 26.5%, and distant metastases in 28.2% of evaluable cases. Surgical resection was performed in 70.8% of patients. The median overall survival was 84 months, with a 5-year cancer-specific survival of 53.7%. Multivariate analysis identified distant stage (adjusted hazard ratio [aHR] = 5.379, 95% confidence interval [CI]: 3.652-7.921, P < .001), regional stage (aHR = 2.474, 95% CI: 1.711-3.578, P < .001), tumor size per centimeter (aHR = 1.078, 95% CI: 1.052-1.104, P < .001), and age per year (aHR = 1.011, 95% CI: 1.004-1.018, P = .002) as adverse prognostic factors. Surgical intervention demonstrated substantial survival benefit (aHR = 0.397, 95% CI: 0.280-0.563, P < .001). This contemporary population-based analysis represents the largest evaluation of epithelioid sarcoma outcomes to date, encompassing more than twice the sample size of prior SEER analyses. Stage at diagnosis emerges as the predominant prognostic determinant, with surgical resection conferring consistent survival benefit across disease stages. Compared with historical cohorts, observed improvements in 5-year survival likely reflect advances in diagnostic recognition and multimodal management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.